On Friday, T-Mobile US Inc (NYSE:TMUS)’s shares declined -1.47% to $40.13.
T-Mobile US, Inc. (TMUS) declared that the quarterly dividend on its 5.50% Mandatory Convertible Preferred Stock (“Preferred Stock”) will be paid on September 15, 2015, to holders of record as of September 1, 2015. The dividend will be paid at a rate of $0.6875 per share of Preferred Stock.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smartphones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers. It offers services, devices, and accessories through its owned and operated retail stores, in addition to through its Websites. +
Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s shares dropped -2.23% to $7.01.
Synergy Pharmaceuticals Inc. (SGYP) a biopharmaceutical company focused on the development of novel treatments for gastrointestinal (GI) diseases and disorders, recently stated its financial results and business update for the three and six months ended June 30, 2015.
Second Quarter 2015 and Recent Highlights
Plecanatide
- On June 17, 2015, we declared positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with CIC. Both doses of plecanatide met the study’s primary endpoint and demonstrated statistical significance in the proportion of patients who were durable overall responders contrast to placebo during the 12-week treatment period (21.0% in 3.0 mg and 19.5% in 6.0 mg dose groups contrast to 10.2% in placebo; p<0.001 for both doses). The durable overall responder endpoint is the current FDA endpoint required for U.S. approval in CIC. Stool comprising was the key secondary endpoint stated with top-line analyses; both plecanatide doses showed statistically noteworthy improvement from baseline in Bristol Stool Form Scale (BSFS) scores contrast to placebo (mean enhance of 1.53 in 3.0 mg and 1.52 in 6.0 mg dose groups contrast to a mean enhance of 0.77 in placebo; p<0.001 for both doses). The observed improvements began at Week 1, continued throughout the 12-week treatment period, and returned towards baseline with no indication of an exaggerated or rebound effect following discontinuation of treatment. The most common adverse event was diarrhea but overall rates were low and did not enhance with dose (5.9% in 3.0 mg and 5.5% in 6.0 mg dose groups contrast to 1.3% in placebo). Only 15 patients in the trial (1.1%) practiced serious adverse events but there was no imbalance across treatment groups in either incidences or individual serious adverse events. Overall, the rates of withdrawal from treatment because of an adverse event were low (5.1 % in 3.0 mg and 5.0% in 6.0 mg dose groups contrast to 1.3% in placebo) and discontinuations due to diarrhea were infrequent (2.7% in 3.0 mg and 2.4% in 6.0 mg dose groups contrast to 0.4% in placebo). No clinically relevant abnormalities were observed in serum chemistries, hematology, urinalysis, ECG or vital signs measurements.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
At the end of Friday’s trade, Energy XXI Ltd (NASDAQ:EXXI)‘s shares dipped -7.10% to $1.44.
Energy XXI (EXXI) declared it will host a conference call on Monday, September 14, 2015 at 9 a.m. CT to talk about fiscal 2015 fourth-quarter and year-end financial and operating results for the period ended June 30, 2015. Results will be released through global newswire services preceding to the call and will be accessible at www.EnergyXXI.com.
Energy XXI (Bermuda) Limited is engaged in the acquisition, exploration, development, production, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico. As of June 30, 2014, the company had proved reserves of 246.2 million barrels of oil equivalent. It operated or had an interest in 984 gross producing wells on 432,954 net developed acres, counting interests in 61 producing fields. Energy XXI (Bermuda) Limited was founded in 2005 and is headquartered in Houston, Texas.
SunPower Corporation (NASDAQ:SPWR), ended its Friday’s trading session with -6.94% loss, and closed at $21.72.
SunPower Corporation (SPWR), a leading solar technology and global energy services provider, and SunPower Elite Dealer Freedom Solar declared recently the completion of a 14 kilowatt solar power system for Austin’s Sustainable Food Center at a ribbon cutting ceremony attended by Mayor Steve Adler.
Sustainable Food Center cultivates a healthy community by strengthening the local food system and improving access to nutritious, affordable food. The nonprofit organization hosts four farmers markets, provides organic food gardening classes, interactive cooking classes and nutrition education, and supports area farmers’, all in the Austin area.
SunPower Corporation designs, manufactures, and delivers solar systems to residential, commercial, and utility-scale power plant customers worldwide. The company offers solar power components, counting panels, balance of system components, and inverters. It also offers rooftop and ground-mounted solar power systems, counting residential systems, commercial roof and ground mounted systems, utility and power plant systems, and utility-scale photovoltaic power plants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
